Рынок аутсорсинга нормативно-правовых актов IVD в Северной Америке по услугам (нормативная документация и подача документов, нормативная регистрация и заявки на клинические испытания, нормативный консалтинг, юридическое представительство, услуги по управлению данными, услуги по производству и контролю химии (CMC) и другие), показания (онкология, неврология, кардиология, клиническая химия и иммуноанализы, прецизионная медицина, инфекционные заболевания, диабет, генетическое тестирование, ВИЧ/СПИД, гематология , тестирование лекарств/фармакогеномика, переливание крови, точка оказания медицинской помощи и другие), режим развертывания (облачный и локальный), размер организации (малые и средние предприятия (SMES) и крупные предприятия), стадия (клиническая, доклиническая и PMA (пострегистрационная авторизация)), класс (класс I, класс II и класс III), конечный пользователь (фармацевтические компании, компании по производству медицинских приборов , биотехнологические компании и другие), страна (США, Канада, Мексика) Тенденции отрасли и прогноз до 2029 года.
Анализ рынка и идеи : рынок аутсорсинга нормативно-правового регулирования IVD в Северной Америке
Ожидается, что рынок аутсорсинга регуляторных вопросов IVD в Северной Америке будет расти в прогнозируемый период с 2022 по 2029 год. По данным Data Bridge Market Research, среднегодовой темп роста рынка составит 13,4% в прогнозируемый период с 2022 по 2029 год, и ожидается, что к 2029 году он достигнет 779 587,15 тыс. долларов США.
- Продукция для диагностики in vitro — это реагенты, устройства и системы, используемые для диагностики заболеваний или других состояний, включая определение состояния здоровья для лечения, смягчения, лечения или профилактики заболеваний. Эти продукты предназначены для использования при сборе, подготовке и исследовании образцов человеческого тела. Нормативные вопросы играют важную роль в индустрии диагностических устройств in vitro (IVD) и медицинских устройств. Услуги аутсорсинга нормативно-правовых вопросов включают в себя написание и публикацию медицинской нормативной документации специалистами, которые вносят вклад в создание высококачественных документов для проектов клинических исследований. Спрос на аутсорсинг нормативно-правовых услуг существенно растет в клинических исследованиях, проводимых в странах с развивающейся экономикой, что обеспечивает здоровую платформу для роста этой отрасли.
Основными факторами, способствующими росту рынка аутсорсинга регуляторных вопросов IVD, являются развитие поддержки на основе проектов, что приводит к долгосрочному соглашению об аутсорсинге между организациями и технологическому прогрессу в различных диагностических устройствах in vitro. Увеличение деятельности по НИОКР компаниями по всему региону создает возможности для роста рынка. Более высокие затраты, связанные с обслуживанием и аутсорсингом IVD, являются основным сдерживающим фактором для рынка аутсорсинга регуляторных вопросов IVD. Нехватка квалифицированного персонала для работы с диагностическими устройствами in vitro является основным препятствием для роста рынка.
This IVD regulatory affairs outsourcing market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
North America IVD Regulatory Affairs Outsourcing Market Scope and Market Size
North America IVD regulatory affairs outsourcing market is segmented into seven notable segments which are based on the services, indication, deployment mode, organization size, stage, class and end user.
- On the basis of services, the North America IVD regulatory affairs outsourcing market is segmented into regulatory writing & submissions, regulatory registration & clinical trial applications, regulatory consulting, legal representation, data management services, chemistry manufacturing and controls (CMC) services, and others. In 2022, regulatory writing & submissions is expected to dominate the market as the industry is responding to several widespread developments, which have triggered innovations and expansion in IVD technologies. These large-scale trends include an aging population, an increase in the occurrence of infectious diseases, the influence of big tech innovators and acceptance of personalized care, and desire for ease of use.
- On the basis of indication, the North America IVD regulatory affairs outsourcing market is segmented into oncology, neurology, cardiology, clinical chemistry and immunoassays, precision medicine, infectious diseases, diabetes, genetic testing, HIV/AIDS, haematology, drug testing/pharmacogenomics, blood transfusion, point of care, and others. In 2022, the oncology segment is expected to dominate as it improves the predictability of the oncology drug development process and becomes a useful tool for oncologists when deciding on a treatment plan for a patient
- On the basis of deployment mode, the North America IVD regulatory affairs outsourcing market is segmented into cloud and on-premises. In 2022, the cloud segment is expected to dominate as it Cloud computing technology in IVD regulatory gives a stable infrastructure with maximum output to IVD systems dealing firms due to its cost-effective and solution-flexible properties.
- On the basis of organization size, the North America IVD regulatory affairs outsourcing market is segmented into small and medium enterprises (SMES) and large enterprises. In 2022, the large enterprises segment is expected to dominate as it involvement of the peer high quality technology and service portfolio related to the IVD regulatory.
- On the basis of stage, the North America IVD regulatory affairs outsourcing market is segmented into clinical, preclinical, and PMA (post-market authorization). In 2022, clinical segment is expected to dominate the market because clinical trials require clearance from authorities, every result must be filed and thoroughly recorded before submissions, regulatory affairs services are in high demand in this area.
- On the basis of class, the North America IVD regulatory affairs outsourcing market is segmented into class I, class II, and class III. In 2022, class I segment is expected to dominate the market as it involves no public health risk or low personal risk with lowest regulations. These are high in demand and 47% of medical devices fall under this category.
- On the basis of end user, the North America IVD regulatory affairs outsourcing market is segmented into pharmaceutical companies, medical device companies, biotechnology companies, and others. In 2022, medical device companies are expected to dominate the market by emerging in various efficient technological services and standards.
North America IVD Regulatory Affairs Outsourcing Market Country Level Analysis
North America IVD regulatory affairs outsourcing market is analysed and market size information is provided by the country, services, indication, deployment mode, organization size, stage, class and end user.
The countries covered in North America IVD regulatory affairs outsourcing market report are U.S., Mexico and Canada.
The U.S. is dominating the market in North America region due to increasing developments in new technologies in healthcare sector and strategic acquisition & partnership among organization.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rising Demand of IVD Regulatory Affairs Outsourcing
North America IVD regulatory affairs outsourcing market also provides you with detailed market analysis for every country growth in industry with sales, components sales, impact of technological development in IVD regulatory affairs outsourcing and changes in regulatory scenarios with their support for the IVD regulatory affairs outsourcing market. The data is available for historic period 2012 to 2020.
Competitive Landscape and North America IVD Regulatory Affairs Outsourcing Market Share Analysis
Конкурентная среда рынка аутсорсинга регуляторных вопросов IVD в Северной Америке содержит сведения по конкурентам. Включены сведения о компании, финансы компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, глобальное присутствие, производственные площадки и объекты, сильные и слабые стороны компании, запуск продукта, конвейеры испытаний продукта, одобрения продукта, патенты, ширина и широта продукта, доминирование приложений, кривая жизненной линии технологии. Приведенные выше точки данных связаны только с фокусом компаний, связанным с рынком аутсорсинга регуляторных вопросов IVD в Северной Америке.
Некоторые из основных игроков, работающих в отчете, на рынке аутсорсинга регуляторных вопросов IVD: Freyr Solutions, AXSource, LORENZ Life Sciences Group, PPD Inc. (дочерняя компания Thremofisher Scientific Inc.), Promedica International, калифорнийская корпорация, Assent Compliance Inc., MakroCare, EMERGO, ICON, Parexel International Corporation, CRITERIUM, INC., Groupe ProductLife SA, Propharma Group, VCLS, Labcorp Drug Development, WuXi AppTec, Charles River Laboratories, Genpact, Medpace, Regulatory Compliance Associates Inc., RQM+, Saraca Solutions Private Limited, PBC BioMed, Dor Pharmaceutical Services, Qserve, mdiConsultants, Inc. и другие. Аналитики DBMR понимают конкурентные преимущества и предоставляют конкурентный анализ для каждого конкурента отдельно.
Многие разработки продуктов также инициируются компаниями по всему миру, что также ускоряет рост рынка аутсорсинга нормативно-правового регулирования IVD в Северной Америке.
Например,
- В сентябре 2021 года Tánaiste объявляет о многомиллионном финансировании НИОКР ICON plc для ускорения технологии децентрализованных клинических испытаний. Tánaiste и министр предпринимательства, торговли и занятости Лео Варадкар TD объявили, что ICON plc (NASDAQ: ICLR), базирующийся в Дублине глобальный поставщик услуг по разработке и коммерциализации лекарственных препаратов для фармацевтической, биотехнологической и медицинской промышленности, получил 4 миллиона долларов США на финансирование НИОКР, администрируемое Enterprise Ireland, для дальнейшего совершенствования своих решений в области данных и технологии децентрализованных клинических испытаний. Это помогло компании улучшить свои позиции на рынке.
- В октябре 2021 года группа Propharma приобрела Pharmica Consulting. ProPharma Group, портфельная компания Odyssey Investment Partners, приобрела Pharmica Consulting, консалтинговую компанию в области естественных наук, которая предоставляет консалтинговые решения по управлению проектами (PM) и фирменное программное обеспечение для операций фармацевтическим и биотехнологическим компаниям для проведения клинических испытаний. Это помогло компании расширить свой бизнес на глобальном рынке.
Партнерство, совместные предприятия и другие стратегии увеличивают долю рынка компании за счет увеличения охвата и присутствия. Это также дает преимущество для организации улучшить свое предложение по аутсорсингу регуляторных вопросов IVD за счет расширенного диапазона размеров.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 DBMR MARKET POSITION GRID
2.7 VENDOR SHARE ANALYSIS
2.8 MULTIVARIATE MODELING
2.9 SERVICE TIMELINE CURVE
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, REGULATORY SCENARIO
4.1.1 THE U.S.
4.1.2 REGULATIONS IN EUROPE
4.1.3 REGULATIONS IN ASIA
4.1.3.1 CHINA
4.1.3.2 SOUTH KOREA
4.1.3.3 MALAYSIA
4.1.3.4 THAILAND
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN PREVALENCE OF CHRONIC DISEASES ACROSS THE REGION
5.1.2 TECHNOLOGICAL ADVANCEMENT IN DEVELOPING VARIOUS IN VITRO DIAGNOSTIC DEVICES
5.1.3 DEVELOPMENT OF PROJECT-BASED SUPPORT LEADS TO LONG TERM OUTSOURCING AGREEMENT AMONG ORGANIZATION
5.1.4 INCREASE IN PRODUCT REGISTRATION NUMBERS AND CLINICAL TRIAL APPROVALS ACROSS THE REGION
5.2 RESTRAINTS
5.2.1 STRINGENT REGULATIONS REGARDING MEDICAL DEVICES IN DIFFERENT REGIONS
5.2.2 HIGHER COST RELATED TO MAINTENANCE AND OUTSOURCING OF IVD
5.3 OPPORTUNITIES
5.3.1 RISE IN STRATEGIC ACQUISITION & PARTNERSHIP AMONG ORGANIZATION
5.3.2 EMERGENCE OF VARIOUS EFFICIENT TECHNOLOGICAL SERVICES AND STANDARDS
5.3.3 INCREASE IN R&D ACTIVITIES BY COMPANIES ACROSS THE REGION
5.4 CHALLENGES
5.4.1 LACK OF INFRASTRUCTURE IN HEALTHCARE SERVICE
5.4.2 SHORTAGE OF SKILLED PERSONNEL FOR HANDLING IN VITRO DIAGNOSTIC DEVICES
6 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE
6.1 OVERVIEW
6.2 REGULATORY WRITING & SUBMISSIONS
6.3 LEGAL REPRESENTATION
6.4 REGULATORY CONSULTING
6.5 REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
6.6 CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
6.7 DATA MANAGEMENT SERVICES
6.8 OTHERS
7 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION
7.1 OVERVIEW
7.2 CLINICAL CHEMISTRY AND IMMUNOASSAYS
7.3 INFECTIOUS DISEASES
7.3.1 VIROLOGY
7.3.2 MICROBIOLOGY AND MYCOLOGY
7.3.3 BACTERIOLOGY
7.3.4 SEPSIS
7.3.5 HEPATITIS B
7.3.6 HEPATITIS C
7.3.7 MALARIA
7.3.8 TUBERCULOSIS
7.3.9 SYPHILIS
7.3.10 HUMAN PAPILLOMAVIRUS (HPV) INFECTION
7.3.11 OTHERS
7.4 HAEMATOLOGY
7.5 DRUG TESTING/PHARMACOGENOMICS
7.6 PRECISION MEDICINE
7.7 DIABETES
7.8 BLOOD TRANSFUSION
7.9 CARDIOLOGY
7.1 POINT OF CARE
7.10.1 WAIVED TEST
7.10.2 AT HOME TESTS
7.11 ONCOLOGY
7.12 NEUROLOGY
7.13 HIV/AIDS
7.14 GENETIC TESTING
7.15 OTHERS
8 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS
8.1 OVERVIEW
8.2 CLASS I
8.3 CLASS III
8.4 CLASS II
9 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE
9.1 OVERVIEW
9.2 CLOUD
9.3 ON-PREMISES
10 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE
10.1 OVERVIEW
10.2 LARGE ENTERPRISES
10.3 SMALL & MEDIUM ENTERPRISES (SMES)
11 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE
11.1 OVERVIEW
11.2 CLINICAL
11.3 PRECLINICAL
11.4 PMA (POST MARKET AUTHORIZATION)
12 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER
12.1 OVERVIEW
12.2 MEDICAL DEVICE COMPANIES
12.2.1 BY ORGANIZATION SIZE
12.2.1.1 LARGE ENTERPRISES
12.2.1.2 SMALL & MEDIUM ENTERPRISES (SMES)
12.2.2 BY SERVICE
12.2.2.1 REGULATORY WRITING & SUBMISSIONS
12.2.2.2 LEGAL REPRESENTATION
12.2.2.3 REGULATORY CONSULTING
12.2.2.4 REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
12.2.2.5 CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
12.2.2.6 DATA MANAGEMENT SERVICES
12.2.2.7 OTHERS
12.3 PHARMACEUTICAL COMPANIES
12.3.1 BY ORGANIZATION SIZE
12.3.1.1 LARGE ENTERPRISES
12.3.1.2 SMALL & MEDIUM ENTERPRISES (SMES)
12.3.2 BY SERVICE
12.3.2.1 REGULATORY WRITING & SUBMISSIONS
12.3.2.2 LEGAL REPRESENTATION
12.3.2.3 REGULATORY CONSULTING
12.3.2.4 REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
12.3.2.5 CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
12.3.2.6 DATA MANAGEMENT SERVICES
12.3.2.7 OTHERS
12.4 BIOTECHNOLOGY COMPANIES
12.4.1 BY ORGANIZATION SIZE
12.4.1.1 LARGE ENTERPRISES
12.4.1.2 SMALL & MEDIUM ENTERPRISES (SMES)
12.4.2 BY SERVICE
12.4.2.1 REGULATORY WRITING & SUBMISSIONS
12.4.2.2 LEGAL REPRESENTATION
12.4.2.3 REGULATORY CONSULTING
12.4.2.4 REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
12.4.2.5 CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
12.4.2.6 DATA MANAGEMENT SERVICES
12.4.2.7 OTHERS
12.5 OTHERS
13 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ICON PLC
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 MEDPACE
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 PAREXEL INTERNATIONAL CORPORATION
16.3.1 COMPANY SNAPSHOT
16.3.2 COMPANY SHARE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENTS
16.4 LABCORP DRUG DEVELOPMENT
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 PPD INC. (A SUBSIDIARY OF THERMOFISHER SCIENTIFIC INC.)
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 CHARLES RIVER LABORATORIES
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 FREYR
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 ASSENT COMPLIANCE INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 ANDAMAN MEDICAL
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 ASIA ACTUAL
16.10.1 COMPANY SNAPSHOT
16.10.2 SERVICE PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 AXSOURCE
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 CRITERIUM, INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 DOR PHARMACEUTICAL SERVICES
16.13.1 COMPANY SNAPSHOT
16.13.2 SERVICE PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 EMERGO BY UL
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 GENPACT
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 GROUPE PRODUCTLIFE S.A.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 LORENZ LIFE SCIENCES GROUP
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 MAKROCARE
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 MARACA INTERNATIONAL BVBA
16.19.1 COMPANY SNAPSHOT
16.19.2 SERVICE PORTFOLIO
16.19.3 RECENT DEVELOPMENTS
16.2 MDICONSULTANTS, INC.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
16.21 PBC BIOMED
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
16.22 PROMEDICA INTERNATIONAL, A CALIFORNIA CORPORATION
16.22.1 COMPANY SNAPSHOT
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENT
16.23 PROPHARMA GROUP
16.23.1 COMPANY SNAPSHOT
16.23.2 PRODUCT PORTFOLIO
16.23.3 RECENT DEVELOPMENTS
16.24 QSERVE
16.24.1 COMPANY SNAPSHOT
16.24.2 SERVICE PORTFOLIO
16.24.3 RECENT DEVELOPMENTS
16.25 REGULATORY COMPLIANCE ASSOCIATES INC.
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENT
16.26 RMQ+
16.26.1 COMPANY SNAPSHOT
16.26.2 PRODUCT PORTFOLIO
16.26.3 RECENT DEVELOPMENT
16.27 SARACA SOLUTIONS PRIVATE LIMITED
16.27.1 COMPANY SNAPSHOT
16.27.2 PRODUCT PORTFOLIO
16.27.3 RECENT DEVELOPMENT
16.28 VCLS
16.28.1 COMPANY SNAPSHOT
16.28.2 PRODUCT PORTFOLIO
16.28.3 RECENT DEVELOPMENTS
16.29 WUXI APPTEC
16.29.1 COMPANY SNAPSHOT
16.29.2 REVENUE ANALYSIS
16.29.3 PRODUCT PORTFOLIO
16.29.4 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
Список таблиц
TABLE 1 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 2 NORTH AMERICA REGULATORY WRITING & SUBMISSIONS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 3 NORTH AMERICA LEGAL REPRESENTATION IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 4 NORTH AMERICA REGULATORY CONSULTING IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 5 NORTH AMERICA REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 6 NORTH AMERICA CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 7 NORTH AMERICA DATA MANAGEMENT SERVICES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY MATERIAL, 2020-2029 (USD THOUSAND)
TABLE 8 NORTH AMERICA OTHERS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 9 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 10 NORTH AMERICA CLINICAL CHEMISTRY AND IMMUNOASSAYS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 11 NORTH AMERICA INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION,2020-2029 (THOUSAND)
TABLE 12 NORTH AMERICA INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 13 NORTH AMERICA HAEMATOLOGY IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 14 NORTH AMERICA DRUG TESTING/PHARMACOGENOMICS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 15 NORTH AMERICA PRECISION MEDICINE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 16 NORTH AMERICA DIABETES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 17 NORTH AMERICA BLOOD TRANSFUSION IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 18 NORTH AMERICA CARDIOLOGY IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 19 NORTH AMERICA POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 20 NORTH AMERICA POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 21 NORTH AMERICA ONCOLOGY IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 22 NORTH AMERICA NEUROLOGY IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 23 NORTH AMERICA HIV/AIDS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 24 NORTH AMERICA GENETIC TESTING IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 25 NORTH AMERICA OTHERS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 26 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 27 NORTH AMERICA CLASS I IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 28 NORTH AMERICA CLASS III IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 29 NORTH AMERICA CLASS II IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 30 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 31 NORTH AMERICA CLOUD IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 32 NORTH AMERICA ON-PREMISES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 33 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 34 NORTH AMERICA LARGE ENTERPRISES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 35 NORTH AMERICA SMALL & MEDIUM ENTERPRISES (SMES) IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 36 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 37 NORTH AMERICA CLINICAL IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 38 NORTH AMERICA PRECLINICAL IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 39 NORTH AMERICA PMA (POST MARKET AUTHORIZATION) IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 41 NORTH AMERICA MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 NORTH AMERICA MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 43 NORTH AMERICA MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 44 NORTH AMERICA PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 45 NORTH AMERICA PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 46 NORTH AMERICA PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 47 NORTH AMERICA BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 48 NORTH AMERICA BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 49 NORTH AMERICA BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 50 NORTH AMERICA OTHERS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 51 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 52 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 53 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 54 NORTH AMERICA INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 55 NORTH AMERICA POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 56 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 57 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 58 NORTH AMERICA REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 59 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 60 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 61 NORTH AMERICA MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 62 NORTH AMERICA MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 63 NORTH AMERICA PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 64 NORTH AMERICA PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 65 NORTH AMERICA BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 66 NORTH AMERICA BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 67 U.S. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 68 U.S. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 69 U.S. INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 70 U.S. POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 71 U.S. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 72 U.S. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 73 U.S. REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 74 U.S. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 75 U.S. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 76 U.S. MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 77 U.S. MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 78 U.S. PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 79 U.S. PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 80 U.S. BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 81 U.S. BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 82 CANADA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 83 CANADA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 84 CANADA INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 85 CANADA POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 86 CANADA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 87 CANADA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 88 CANADA REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 89 CANADA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 90 CANADA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 91 CANADA MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 92 CANADA MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 93 CANADA PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 94 CANADA PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 95 CANADA BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 96 CANADA BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 97 MEXICO IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 98 MEXICO IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 99 MEXICO INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 100 MEXICO POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 101 MEXICO IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 102 MEXICO IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 103 MEXICO REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 104 MEXICO IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 105 MEXICO IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 106 MEXICO MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 107 MEXICO MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 108 MEXICO PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 109 MEXICO PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 110 MEXICO BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 111 MEXICO BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
Список рисунков
FIGURE 1 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: SEGMENTATION
FIGURE 11 RISE IN THE PREVALENCE OF CHRONIC DISEASES ACROSS IS EXPECTED TO DRIVE NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SERVICE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET IN 2022 & 2029
FIGURE 13 ASIA-PACIFIC IS EXPECTED TO DOMINATE AND IS THE FASTEST GROWING REGION IN THE NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET
FIGURE 15 MULTIPLE CHRONIC CONDITIONS AMONG PEOPLE AGED 65 AND ABOVE IN EUROPEAN REGION (2017)
FIGURE 16 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY SERVICE, 2021
FIGURE 17 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY INDICATION, 2021
FIGURE 18 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY CLASS, 2021
FIGURE 19 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY DEPLOYMENT MODE, 2021
FIGURE 20 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY ORGANIZATION SIZE, 2021
FIGURE 21 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY STAGE, 2021
FIGURE 22 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY END USER, 2021
FIGURE 23 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: SNAPSHOT (2021)
FIGURE 24 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY COUNTRY (2021)
FIGURE 25 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 26 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 27 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY SERVICE (2022-2029)
FIGURE 28 NORTH AMERICA IVD REGULATORY AFFAIRS OUTSOURCING MARKET: COMPANY SHARE 2021 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.